Moricizine-d8(Hydrochloride)

• UNSPSC Description:

  Moricizine-d8 (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1][2].

• Target Antigen:

  Isotope-Labeled Compounds

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Others

• Field of Research:

  Cardiovascular Disease

• Solubility:

  10 mM in DMSO

• Smiles:

  [2H]C1([2H])C([2H])([2H])OC([2H])([2H])C([2H])([2H])N1CCC(N2C3=CC(NC(OCC)=O)=CC=C3SC4=CC=CC=C42)=O.Cl

• Molecular Weight:

  472.03

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Bigger JT Jr. Cardiac electrophysiologic effects of moricizine hydrochloride. Am J Cardiol. 1990 Feb 20;65(8):15D-20D; discussion 68D-71D.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2300178-76-9